NASDAQ:RGEN - Repligen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $94.33 -2.21 (-2.29 %) (As of 04/2/2020 01:27 AM ET) Add Compare Today's Range$92.00Now: $94.33▼$96.0150-Day Range$84.96MA: $94.97▼$109.1452-Week Range$52.87Now: $94.33▼$109.94Volume551,395 shsAverage Volume529,432 shsMarket Capitalization$4.91 billionP/E Ratio214.39Dividend YieldN/ABeta1.34 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies, recombinant proteins, and vaccines; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell alternating tangential flow systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius tangential flow filters line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH and Sartorius Stedim Biotech to develop multiple affinity ligands. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN Previous Symbol CUSIP75991610 CIK730272 Webhttp://www.repligen.com/ Phone781-250-0111Debt Debt-to-Equity Ratio0.25 Current Ratio13.28 Quick Ratio12.15Price-To-Earnings Trailing P/E Ratio214.39 Forward P/E Ratio88.16 P/E Growth4.08 Sales & Book Value Annual Sales$270.24 million Price / Sales18.18 Cash Flow$1.39 per share Price / Cash Flow67.97 Book Value$20.36 per share Price / Book4.63Profitability EPS (Most Recent Fiscal Year)$1.07 Net Income$21.41 million Net Margins7.92% Return on Equity5.82% Return on Assets4.52%Miscellaneous Employees548 Outstanding Shares52,084,000Market Cap$4.91 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive RGEN News and Ratings via Email Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RGEN Rates by TradingView Repligen (NASDAQ:RGEN) Frequently Asked Questions How has Repligen's stock been impacted by COVID-19 (Coronavirus)? Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGEN shares have increased by 3.7% and is now trading at $94.33. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Repligen? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Repligen. When is Repligen's next earnings date? Repligen is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Repligen. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings results on Thursday, February, 20th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.02. The biotechnology company earned $69.47 million during the quarter, compared to analysts' expectations of $68.37 million. Repligen had a return on equity of 5.82% and a net margin of 7.92%. The company's quarterly revenue was up 33.8% on a year-over-year basis. During the same period last year, the company earned $0.21 earnings per share. View Repligen's earnings history. What guidance has Repligen issued on next quarter's earnings? Repligen updated its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of $1.07-1.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.10. The company issued revenue guidance of $309-319 million, compared to the consensus revenue estimate of $314.77 million. What price target have analysts set for RGEN? 6 equities research analysts have issued 1 year price targets for Repligen's stock. Their forecasts range from $100.00 to $116.00. On average, they expect Repligen's share price to reach $108.00 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View analysts' price targets for Repligen. What are Wall Street analysts saying about Repligen stock? Here are some recent quotes from research analysts about Repligen stock: 1. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share." (8/12/2019) 2. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (8/7/2019) Has Repligen been receiving favorable news coverage? News coverage about RGEN stock has been trending very negative on Thursday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Repligen earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutRepligen. Are investors shorting Repligen? Repligen saw a increase in short interest in March. As of March 13th, there was short interest totaling 2,638,100 shares, an increase of 28.7% from the February 27th total of 2,050,000 shares. Based on an average trading volume of 640,600 shares, the short-interest ratio is currently 4.1 days. Currently, 5.6% of the company's shares are short sold. View Repligen's Current Options Chain. Who are some of Repligen's key competitors? Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Veeva Systems (VEEV), Micron Technology (MU), Xilinx (XLNX), Trade Desk (TTD), salesforce.com (CRM), Twilio (TWLO) and Okta (OKTA). Who are Repligen's key executives? Repligen's management team includes the following people: Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)Mr. Jon K. Snodgres, CFO & Sec. (Age 53)Mr. Steve Curran, VP of Global OperationsMs. Sondra S. Newman, Sr. Director of Investor RelationsMr. Stephen Tingley, VP of Sales What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." Who are Repligen's major shareholders? Repligen's stock is owned by many different institutional and retail investors. Top institutional investors include Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View institutional ownership trends for Repligen. Which institutional investors are buying Repligen stock? RGEN stock was acquired by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Repligen. How do I buy shares of Repligen? Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $94.33. How big of a company is Repligen? Repligen has a market capitalization of $4.91 billion and generates $270.24 million in revenue each year. The biotechnology company earns $21.41 million in net income (profit) each year or $1.07 on an earnings per share basis. Repligen employs 548 workers across the globe. View additional information about Repligen. What is Repligen's official website? The official website for Repligen is http://www.repligen.com/. How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected] MarketBeat Community Rating for Repligen (NASDAQ RGEN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 340 (Vote Outperform)Underperform Votes: 319 (Vote Underperform)Total Votes: 659MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/2/2020 by MarketBeat.com StaffFeatured Article: What are gap-down stocks?
